losartan has been researched along with Kidney Failure, Chronic in 150 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study provided the opportunity to estimate costs associated with ESRD by baseline albuminuria from a United States perspective." | 10.21 | Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. ( Alexander, CM; Carides, GW; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2004) |
| "Losartan significantly decreased proteinuria and UAGT excretion, and preserved renal function in non-diabetic patients with CKD." | 9.15 | Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease. ( Cho, S; Huh, W; Jang, HR; Kim, DJ; Kim, SR; Kim, YG; Lee, JE; Lee, YJ; Oh, HY, 2011) |
| " There is currently little information available on the efficacy, safety, and individual tolerance of patients with post-diarrheal hemolytic uremic syndrome (D+ HUS) nephropathy to therapies involving diet, enalapril, or losartan." | 9.15 | Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy. ( Caletti, MG; Exeni, R; Grignoli, M; Missoni, M; Piantanida, JJ; Rasse, SM; Repetto, HA; Vezzani, C, 2011) |
| " Thirty chronically hemodialyzed uremic patients with hypertension were randomly assigned to receive the AT1-R antagonist losartan (n = 10), the angiotensin-converting enzyme (ACD) inhibitor enalapril (n = 10), or calcium antagonist amlodipine (n = 10)." | 9.10 | Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. ( Iwasaka, T; Masaki, H; Matsubara, H; Nishikawa, M; Nishiue, T; Shibasaki, Y, 2002) |
| "Recently, the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study demonstrated the benefit of losartan in reducing renal outcomes in patients with type 2 diabetes and proteinuria." | 9.10 | Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. ( Ahmed, T; Brenner, BM; Dickson, TZ; Ramjit, D; Shahinfar, S; Smith, RD; Zhang, Z, 2002) |
| "We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration." | 7.71 | Repeated transient anuria following losartan administration in a patient with a solitary kidney. ( Descombes, E; Fellay, G; Maillard, JO; Regamey, C, 2001) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 6.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "Hyperkalemia is a known side effect during treatment with Angiotensin Converting Enzyme Inhibitors (ACEIs)." | 6.71 | Incidence of hyperkalemia in high risk patients during treatment with an angiotensin converting enzyme inhibitor (Lisinopril) versus an angiotensin II receptor blocker (Losartan). ( Dworkin, L; Yango, A; Zanabli, AR, 2004) |
| "Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13)." | 6.71 | Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. ( Iwasaka, T; Masaki, H; Matsubara, H; Matsumoto, N; Mori, Y; Nishikawa, M; Nishiue, T; Shibasaki, Y; Tamura, K, 2005) |
| " The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study provided the opportunity to estimate costs associated with ESRD by baseline albuminuria from a United States perspective." | 6.21 | Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. ( Alexander, CM; Carides, GW; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2004) |
| "Losartan was effective in controlling blood pressure, and decreasing OSI, a marker of elevated oxidative stress, and increasing plasma levels of SH groups, an antioxidant, in ESRD patients undergoing hemodialysis." | 5.39 | The effects of Losartan on oxidative stress and inflammation in non-diabetic patients undergoing chronic hemodialysis. ( Kadiroglu, AK; Kayabasi, H; Sit, D; Yilmaz, E; Yilmaz, Z, 2013) |
| "Cotreatment with GW9662 partly blunted the normalization of vascular dysfunction and inflammation." | 5.38 | Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat. ( Kobara, M; Nakata, T; Noda, K; Toba, H; Tojo, C; Wang, J, 2012) |
| "A rat model for chronic renal failure, induced by chronic hyperoxaluria (CH-CRF), was produced by unilateral nephrectomy combined with dietary ethylene glycol for 4 weeks." | 5.32 | Angiotensin II involvement in adaptive enteric oxalate excretion in rats with chronic renal failure induced by hyperoxaluria. ( Freel, RW; Hatch, M, 2003) |
| "Changes in systolic blood pressure (SBP), albuminuria, potassium, haemoglobin, cholesterol and uric acid after 6 months of losartan treatment were assessed in the RENAAL database." | 5.20 | The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. ( de Zeeuw, D; Lambers Heerspink, HJ; Parving, HH; Rossing, P; Schievink, B, 2015) |
| "Losartan significantly decreased proteinuria and UAGT excretion, and preserved renal function in non-diabetic patients with CKD." | 5.15 | Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease. ( Cho, S; Huh, W; Jang, HR; Kim, DJ; Kim, SR; Kim, YG; Lee, JE; Lee, YJ; Oh, HY, 2011) |
| " There is currently little information available on the efficacy, safety, and individual tolerance of patients with post-diarrheal hemolytic uremic syndrome (D+ HUS) nephropathy to therapies involving diet, enalapril, or losartan." | 5.15 | Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy. ( Caletti, MG; Exeni, R; Grignoli, M; Missoni, M; Piantanida, JJ; Rasse, SM; Repetto, HA; Vezzani, C, 2011) |
| "This post hoc analysis examined whether baseline proteinuria was predictive of cardiovascular outcomes, and whether losartan modifies the risk of cardiovascular outcomes in these patients given its renal-protective effects." | 5.11 | Losartan and end-organ protection--lessons from the RENAAL study. ( Brenner, BM; Dickson, TZ; Kowey, PR; Shahinfar, S; Zhang, Z, 2005) |
| "Recently, the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study demonstrated the benefit of losartan in reducing renal outcomes in patients with type 2 diabetes and proteinuria." | 5.10 | Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. ( Ahmed, T; Brenner, BM; Dickson, TZ; Ramjit, D; Shahinfar, S; Smith, RD; Zhang, Z, 2002) |
| " Thirty chronically hemodialyzed uremic patients with hypertension were randomly assigned to receive the AT1-R antagonist losartan (n = 10), the angiotensin-converting enzyme (ACD) inhibitor enalapril (n = 10), or calcium antagonist amlodipine (n = 10)." | 5.10 | Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. ( Iwasaka, T; Masaki, H; Matsubara, H; Nishikawa, M; Nishiue, T; Shibasaki, Y, 2002) |
| "We tested this for the AIIA losartan using a prospective single-blind randomized design in patients with proteinuria (>1 g/24 h) due to non-diabetic chronic renal failure (stable creatinine clearance >20 ml/min) and mild to moderate hypertension (130/80 < blood pressure < 160/110 mmHg)." | 5.10 | The antiproteinuric effect of losartan is systemic blood pressure dependent. ( Crowe, AV; Howse, M; Kemp, GJ; Vinjamuri, S; Williams, PS, 2003) |
| "High-dose losartan increases rHuEPO requirement and should be reserved for dialysis patients with hypertension uncontrollable with other antihypertensive medications." | 5.10 | The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. ( Bilen, H; Cetinkaya, R; Keles, S; Odabas, AR; Selcuk, Y, 2003) |
| "Add-on losartan therapy did not improve proteinuria or ABP over one month of add on therapy." | 5.09 | Add-on angiotensin receptor blockade with maximized ACE inhibition. ( Agarwal, R, 2001) |
| "Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria." | 4.82 | Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003) |
| " We studied the effect of a hybrid compound, GGN1231 (derived from losartan in which a powerful antioxidant was attached), on the prevention of cardiovascular damage, cardiac hypertrophy, and fibrosis in a rat model of severe chronic renal failure (CRF)." | 4.31 | Effects of a Losartan-Antioxidant Hybrid (GGN1231) on Vascular and Cardiac Health in an Experimental Model of Chronic Renal Failure. ( Alajarín, R; Alonso-Montes, C; Alvarez-Builla, J; Cannata-Andía, JB; Carrillo-López, N; Fernández-Villabrille, S; García-Navazo, G; Gutiérrez-Calabres, E; Martínez-Arias, L; Naves-Díaz, M; Panizo, S; Rodríguez-Puyol, D; Ruíz-Torres, MP; Vaquero-López, JJ, 2023) |
| "Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)." | 4.21 | ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin II AT(1) receptor antagonist." | 3.80 | Losartan in diabetic nephropathy. ( Carswell, CI; Goa, KL, 2003) |
| " Patients were administered either losartan or placebo, each in addition to conventional antihypertensive therapy, with dosage adjustments as necessary to achieve a target blood pressure of less than 140/less than 90 mm Hg." | 3.80 | Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. ( Keane, WF; Lyle, PA, 2003) |
| " Losartan significantly attenuated the expression of TGF-β1 and Snail, and decreased kidney fibrosis induced by IS and PCS in vivo." | 3.78 | Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. ( Chang, SC; Sun, CY; Wu, MS, 2012) |
| "Mean proteinuria decreased from 484 +/- 290 mg/mmol creatinine to 223 +/- 197 after 1-3 months of losartan treatment and remained stable at 234 +/- 153, 224 +/- 177 and 195 +/- 133 after 3-6, 6-12 months and at the last follow-up check (median 1." | 3.75 | Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors. ( John, U; Misselwitz, J; Pohl, M; Seeman, T, 2009) |
| "These preliminary results suggest a possible influence of CYP2C9 genotype on proteinuria and blood pressure in Caucasian CKD patients treated with losartan." | 3.75 | CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. ( Blaisdell, J; Boyette, T; Candiani, C; Dornbrook-Lavender, K; Falk, RJ; Goldstein, JA; Hilliard, T; Hogan, SL; Hu, Y; Joy, MS, 2009) |
| "Arterial hypertension significantly decreased after the introduction of losartan (p = 0." | 3.72 | Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. ( Anaya, F; Campistol, JM; Del Castillo, D; Esforzado, N; Iñigo, P; Navarro, MD; Oppenheimer, F; Saracho, R, 2003) |
| "We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration." | 3.71 | Repeated transient anuria following losartan administration in a patient with a solitary kidney. ( Descombes, E; Fellay, G; Maillard, JO; Regamey, C, 2001) |
| " Angiotensin-converting enzyme (ACE) inhibitors appear to be the drugs of choice since they not only lower blood pressure but also reduce some important risk factors that may cause progressive loss of renal function, such as intraglomerular hypertension, angiotensin II (Ang II)-induced glomerular growth, proteinuria and hyperlipidemia." | 3.69 | Losartan in patients with renal insufficiency. ( de Jong, PE; de Zeeuw, D; Gansevoort, RT, 1995) |
| "We explored the role of angiotensin II and vasopressin in the maintenance of blood pressure during the nephrotic syndrome of adriamycin-induced nephropathy in rats." | 3.69 | Pressor mechanisms in adriamycin-induced nephropathy with hypertension in rats. ( Ferrari-Spadotto, A; Franco, R; Gavras, H; Gavras, I; Georgette, J; Gut, A, 1994) |
| "Proteinuric diabetic kidney disease frequently progresses to ESRD." | 2.80 | BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial. ( Emanuele, NV; Fried, LF; Guarino, P; Leehey, DJ; Palevsky, PM; Reilly, RF; Whaley-Connell, A; Zhang, JH, 2015) |
| "2,628 adults with type 2 diabetes and nephropathy." | 2.80 | Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St ( Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH, 2015) |
| "Diabetic nephropathy is the most frequent cause of end stage renal disease (ESRD)." | 2.76 | Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA. ( Cammarota, S; Citarella, A; de Portu, S; Mantovani, LG; Menditto, E, 2011) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 2.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "This study was performed to ascertain whether losartan combined with pioglitazone is superior to losartan alone in delaying the progression of chronic renal failure in patients with type 2 diabetic nephropathy." | 2.73 | Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. ( Jin, HM; Pan, Y, 2007) |
| "Levels of proteinuria were reduced with losartan compared with placebo, with an overall losartan treatment effect of 37." | 2.72 | Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. ( Chan, JC; Cooper, ME; Keane, WF; Kurokawa, K; Shahinfar, S; Zhang, Z, 2006) |
| " We tested for effect modification by age of the effect of losartan on the incidence of the predefined end points (doubling of serum creatinine, end-stage renal disease [ESRD], or death) and the risk of adverse events." | 2.72 | Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. ( Avorn, J; Brenner, BM; Cooper, ME; Shahinfar, S; Winkelmayer, WC; Zhang, Z, 2006) |
| "The Reduction of Endpoints in NIDDM [non-insulin-dependent diabetes mellitus] with the Angiotensin II Antagonist Losartan (RENAAL) study demonstrated the renoprotective effects of losartan in patients with nephropathy from type 2 diabetes." | 2.71 | Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective. ( Burgess, ED; Carides, GW; Chabot, I; Gerth, WC; Marentette, MA, 2004) |
| "Hyperkalemia is a known side effect during treatment with Angiotensin Converting Enzyme Inhibitors (ACEIs)." | 2.71 | Incidence of hyperkalemia in high risk patients during treatment with an angiotensin converting enzyme inhibitor (Lisinopril) versus an angiotensin II receptor blocker (Losartan). ( Dworkin, L; Yango, A; Zanabli, AR, 2004) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD)." | 2.71 | Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Keane, WF; Mohanram, A; Shahinfar, S; Toto, RD; Zhang, Z, 2004) |
| "Diabetic nephropathy with ESRD for type 2 diabetes mellitus (DM) now has to be recognized as a growing public health problem." | 2.71 | The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study. ( Keusch, GW; Sandoz, MS; Szucs, TD, 2004) |
| "In proteinuric individuals with type 2 diabetes, losartan therapy reduced ESRD and hospitalizations for heart failure and was well tolerated at all levels of renal function." | 2.71 | Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. ( Brenner, BM; Carides, GW; de Zeeuw, D; Dimitrov, BD; Hille, DA; Perna, A; Remuzzi, G; Ruggenenti, P; Shahinfar, S, 2004) |
| "Hemodialysis patients have uremic dyslipidemia, represented by elevated serum intermediate-density lipoprotein cholesterol (IDL-C) levels, and an increased cardiovascular mortality rate." | 2.71 | Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. ( Furukawa, T; Hayashi, M; Homma, K; Ichihara, A; Kaneshiro, Y; Kanno, Y; Saruta, T; Takemitsu, T; Takenaka, T; Yoshizawa, M, 2005) |
| "Treatment with losartan in patients with type 2 diabetic nephropathy not only reduced the incidence of ESRD among Asian patients, but resulted in direct medical cost savings in countries or regions representing Asia." | 2.71 | Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective. ( Burke, TA; Carides, GW; Chan, J; Choi, YJ; Han, DC; Hwang, SJ; Seng, WK; Teong, CC, 2005) |
| "Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13)." | 2.71 | Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. ( Iwasaka, T; Masaki, H; Matsubara, H; Matsumoto, N; Mori, Y; Nishikawa, M; Nishiue, T; Shibasaki, Y; Tamura, K, 2005) |
| "The etiology of CKD was type 2 diabetes mellitus in 12 and glomerulonephritis in 4 patients." | 2.71 | Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. ( Agarwal, R, 2003) |
| "Treatment with losartan in patients with type 2 diabetes and nephropathy not only reduced the incidence of ESRD, but also resulted in substantial cost savings." | 2.71 | Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. ( Alexander, CM; Brenner, BM; Carides, GW; Cook, JR; Dasbach, EJ; Gerth, WC; Herman, WH; Keane, WF; Shahinfar, S, 2003) |
| "The reduction in the number of ESRD days over 4 years in patients treated with losartan significantly decreased costs associated with ESRD by 7,438 euros per patient (CI 95%: 3,029 euros - 11,847 euros, p=0." | 2.71 | An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. ( Durand Zaleski, I; Gaugris, S; Hannedouche, T; Passa, P; Rodier, M; Souchet, T, 2003) |
| "Losartan was administered once daily at doses of 25 to 100 mg/day, and amlodipine was given once daily at 2." | 2.71 | Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for ( Hayashi, M; Ideura, T; Iino, Y; Kawaguchi, Y; Kawamura, T; Kitajima, T; Koyama, A; Kuwahara, M; Shiigai, T; Sugisaki, T; Suzuki, H; Tomino, Y; Uchida, S; Umemura, S; Yamada, K; Yamazaki, T, 2003) |
| "In the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, approximately 17% of patients were Asians." | 2.71 | Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. ( Brenner, BM; Chan, JC; Chua, CT; Cooper, ME; Dickson, TZ; Hille, D; Kurokawa, K; Lam, KS; Morad, Z; Shahinfar, S; So, WY; Wat, NM; Wong, KS; Zhang, Z, 2004) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | 2.70 | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001) |
| "Treatment with losartan (50 mg) was introduced." | 2.69 | Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. ( Campistol, JM; Clesca, PH; Iñigo, P; Jimenez, W; Lario, S; Oppenheimer, F; Rivera, F, 1999) |
| "Losartan was well tolerated in all study subjects." | 2.69 | The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. ( Brophy, DF; Gehr, TW; Pedro, AA; Sica, DA, 2000) |
| "Losartan is a selective angiotensin AT1 receptor antagonist currently employed in the management of essential hypertension." | 2.69 | Pharmacokinetics and blood pressure response of losartan in end-stage renal disease. ( Gehr, TW; Halstenson, CE; Keane, WF; Sica, DA, 2000) |
| "Losartan is a selective non-peptide angiotensin Type 1-receptor blocker (ARB) with unique uricosuric effect, not shared by other ARBs." | 2.43 | Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade. ( Chiurchiu, C; Parvanova, A; Remuzzi, G; Ruggenenti, P, 2005) |
| "The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study was conducted from 1996 to 2001." | 2.43 | Losartan: lessons learned from the RENAAL study. ( Brenner, BM; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2006) |
| "Proteinuria is a sign of established kidney damage and plays a direct pathogenic role in the progression of renal and cardiovascular disease." | 2.43 | Time to abandon microalbuminuria? ( Remuzzi, G; Ruggenenti, P, 2006) |
| "For patients with type 2 diabetes mellitus (T2DM) and hypertension, an AII receptor blocker (AIIRB) is recommended as the first drug that should be used." | 2.42 | Advances in the treatment of diabetic renal disease: focus on losartan. ( Rayner, B, 2004) |
| "The earliest marker of incipient diabetic nephropathy is the transition of normoalbuminuria to microalbuminuria at an albumin excretion rate of 20 microg/min." | 2.42 | Losartan in diabetic nephropathy. ( Perico, N; Remuzzi, G; Ruggenenti, P, 2004) |
| "Recently, the Reduction of Endpoints in NIDDM (non-insulin-dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan (RENAAL) trial provided sufficient data to conclude that the blockade of the All AT1 receptor with losartan confers renoprotection in patients with DM-2 and nephropathy." | 2.41 | The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. ( Ribeiro, AB; Zanella, MT, 2002) |
| " In addition, the nephrectomized db /db mice from 10 weeks to 42 weeks were used to assess the efficacy of long-term administration of the angiotensin-II-receptor antagonist losartan." | 1.72 | Pathophysiological analysis of uninephrectomized db/db mice as a model of severe diabetic kidney disease. ( Kitamoto, M; Konishi, N; Maekawa, M; Maekawa, T; Nakagawa, T; Ohta, T; Sasase, T; Takagi, K; Takeuchi, S; Toyoda, K; Yamada, T, 2022) |
| "Losartan 50 mg/d was used to control proteinuria under the close watch of serum creatinine." | 1.51 | [The 467th case: proteinuria, periungual fibromas, and facial steatadenomas]. ( Chen, G; Dong, QR; Li, MX; Li, XM, 2019) |
| "Pretreatment with Losartan (an AT1 receptor blocker) attenuated the AngII-induced expression of TLR4 and inflammatory cytokines." | 1.42 | Angiotensin II-induced hypertensive renal inflammation is mediated through HMGB1-TLR4 signaling in rat tubulo-epithelial cells. ( Ebenezer, PJ; Francis, J; Nair, AR; Saini, Y, 2015) |
| "Bilirubin was inversely associated with the renal end point in RENAAL independent of age, sex, race, BMI, smoking, total cholesterol, diastolic blood pressure, HbA1c, treatment, estimated glomerular filtration rate, albumin-to-creatinine ratio, and AST." | 1.40 | Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. ( Bakker, SJ; Cooper, ME; de Zeeuw, D; Deetman, PE; Lambers Heerspink, HJ; Lewis, JB; Navis, G; Riphagen, IJ, 2014) |
| "Losartan was effective in controlling blood pressure, and decreasing OSI, a marker of elevated oxidative stress, and increasing plasma levels of SH groups, an antioxidant, in ESRD patients undergoing hemodialysis." | 1.39 | The effects of Losartan on oxidative stress and inflammation in non-diabetic patients undergoing chronic hemodialysis. ( Kadiroglu, AK; Kayabasi, H; Sit, D; Yilmaz, E; Yilmaz, Z, 2013) |
| "Cotreatment with GW9662 partly blunted the normalization of vascular dysfunction and inflammation." | 1.38 | Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat. ( Kobara, M; Nakata, T; Noda, K; Toba, H; Tojo, C; Wang, J, 2012) |
| "Type 2 diabetes is becoming the leading cause of end-stage renal disease (ESRD) worldwide." | 1.33 | Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. ( Brenner, BM; Chan, J; de Zeeuw, D; Kurokawa, K; Lash, JP; Ramjit, D; Remuzzi, G; Ribeiro, AB; Shahinfar, S; Zhang, Z, 2006) |
| "Treatment with losartan, captopril, and the TRx prevented the rhEPO-induced increased in systolic BP." | 1.33 | Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. ( Agharazii, M; Larivière, R; Lebel, M; Rodrigue, ME, 2006) |
| "Treatment with losartan plus CT in patients with type 2 diabetes and nephropathy reduced the within-trial incidence of ESRD and is projected to result in lifetime reductions in ESRD and associated costs, and increased survival, versus placebo." | 1.33 | The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. ( Alexander, CM; Brenner, BM; Carides, GW; Dasbach, EJ; Gerth, WC; Herman, WH; Keane, WF; Shahinfar, S, 2006) |
| "The current case indicates that late recurrences of scleroderma renal crisis are possible in renal transplant recipients and that angiotensin-converting enzyme inhibitors, rather than angiotensin II receptor blockers, may be the superior drugs for such patients." | 1.33 | Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. ( Cheung, WY; Gibson, IW; Jeffery, J; Karpinski, M; Rush, D, 2005) |
| "Losartan treatment lowered significantly LPO in kidney tissue after 2 and 4 weeks of treatment compared with untreated and atenolol-treated animals and induced the decrease of excretion of isoprostanes in urine at the end of the study." | 1.32 | Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure. ( Aunapuu, M; Kullissaar, T; Ots, M; Pechter, U; Riispere, Z; Vihalemm, T; Zilmer, K; Zilmer, M, 2004) |
| "A rat model for chronic renal failure, induced by chronic hyperoxaluria (CH-CRF), was produced by unilateral nephrectomy combined with dietary ethylene glycol for 4 weeks." | 1.32 | Angiotensin II involvement in adaptive enteric oxalate excretion in rats with chronic renal failure induced by hyperoxaluria. ( Freel, RW; Hatch, M, 2003) |
| "Treatment with losartan not only reduced the incidence of ESRD, but also can result in substantial cost savings in the European Union." | 1.31 | Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. ( Brenner, B; Carides, GW; Gerth, WC; Hannedouche, T; Martinez-Castelao, A; Remuzzi, G; Shahinfar, S; Viberti, G, 2002) |
| "Patients with chronic renal failure are restricted to mild physical activity and tend to a lack of exercise." | 1.31 | Renal protective effects of chronic exercise and antihypertensive therapy in hypertensive rats with chronic renal failure. ( Kamimoto, M; Kanazawa, M; Kawamura, T; Kohzuki, M; Kurosawa, H; Minami, N; Mori, N; Nagasaka, M; Saito, T; Wu, XM; Xu, HL; Yoshida, K, 2001) |
| "Patients with Type 2 diabetes and nephropathy should receive either an AT(1) antagonist or the angiotensin converting enzyme inhibitor ramipril to ensure renoprotection." | 1.31 | Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy. ( Doggrell, SA, 2002) |
| " Group 2 (n = 5) was treated with enalapril at a dosage of 50 mg/l in drinking water starting at 6 weeks of age." | 1.29 | Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats. ( Baba, N; Sakemi, T, 1993) |
| "Losartan treatment of CRF rats before the removal of colonic tissues reversed the basal net secretion of urate to net absorption." | 1.29 | Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport. ( Freel, RW; Hatch, M; Shahinfar, S; Vaziri, ND, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (10.00) | 18.2507 |
| 2000's | 102 (68.00) | 29.6817 |
| 2010's | 29 (19.33) | 24.3611 |
| 2020's | 4 (2.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J | 3 |
| Peng, Z | 1 |
| Lu, M | 1 |
| Xiong, X | 1 |
| Chen, Z | 1 |
| Li, Q | 1 |
| Cheng, Z | 1 |
| Jiang, D | 1 |
| Tao, L | 1 |
| Hu, G | 1 |
| Maekawa, M | 1 |
| Maekawa, T | 1 |
| Sasase, T | 1 |
| Takagi, K | 1 |
| Takeuchi, S | 1 |
| Kitamoto, M | 1 |
| Nakagawa, T | 1 |
| Toyoda, K | 1 |
| Konishi, N | 1 |
| Ohta, T | 1 |
| Yamada, T | 1 |
| Orentas, M | 1 |
| Patel, N | 2 |
| Rodby, R | 1 |
| Hassan, S | 1 |
| Martínez-Arias, L | 1 |
| Fernández-Villabrille, S | 1 |
| Alonso-Montes, C | 1 |
| García-Navazo, G | 1 |
| Ruíz-Torres, MP | 1 |
| Alajarín, R | 1 |
| Alvarez-Builla, J | 1 |
| Gutiérrez-Calabres, E | 1 |
| Vaquero-López, JJ | 1 |
| Carrillo-López, N | 1 |
| Rodríguez-Puyol, D | 1 |
| Cannata-Andía, JB | 1 |
| Panizo, S | 1 |
| Naves-Díaz, M | 1 |
| Zhu, Y | 2 |
| Cui, H | 1 |
| Lv, J | 1 |
| Liang, H | 1 |
| Zheng, Y | 1 |
| Wang, S | 2 |
| Wang, M | 2 |
| Wang, H | 4 |
| Ye, F | 1 |
| Nese, M | 1 |
| Riboli, G | 1 |
| Brighetti, G | 1 |
| Sassi, V | 1 |
| Camela, E | 1 |
| Caselli, G | 1 |
| Sassaroli, S | 1 |
| Borlimi, R | 1 |
| Aucoin, M | 1 |
| Cooley, K | 1 |
| Saunders, PR | 1 |
| Carè, J | 1 |
| Anheyer, D | 1 |
| Medina, DN | 1 |
| Cardozo, V | 1 |
| Remy, D | 1 |
| Hannan, N | 1 |
| Garber, A | 1 |
| Velayos, M | 1 |
| Muñoz-Serrano, AJ | 1 |
| Estefanía-Fernández, K | 1 |
| Sarmiento Caldas, MC | 1 |
| Moratilla Lapeña, L | 1 |
| López-Santamaría, M | 1 |
| López-Gutiérrez, JC | 1 |
| Li, J | 1 |
| Zhang, J | 2 |
| Shen, S | 1 |
| Zhang, B | 2 |
| Yu, WW | 1 |
| Toyoda, H | 1 |
| Huang, DQ | 1 |
| Le, MH | 1 |
| Nguyen, MH | 1 |
| Huang, R | 1 |
| Zhu, L | 1 |
| Wang, J | 7 |
| Xue, L | 1 |
| Liu, L | 2 |
| Yan, X | 2 |
| Huang, S | 1 |
| Li, Y | 6 |
| Xu, T | 1 |
| Li, C | 2 |
| Ji, F | 1 |
| Ming, F | 1 |
| Zhao, Y | 2 |
| Cheng, J | 1 |
| Wang, Y | 3 |
| Zhao, H | 1 |
| Hong, S | 1 |
| Chen, K | 2 |
| Zhao, XA | 1 |
| Zou, L | 1 |
| Sang, D | 1 |
| Shao, H | 1 |
| Guan, X | 1 |
| Chen, X | 2 |
| Chen, Y | 4 |
| Wei, J | 1 |
| Zhu, C | 1 |
| Wu, C | 1 |
| Moore, HB | 1 |
| Barrett, CD | 1 |
| Moore, EE | 1 |
| Jhunjhunwala, R | 1 |
| McIntyre, RC | 1 |
| Moore, PK | 1 |
| Hajizadeh, N | 1 |
| Talmor, DS | 1 |
| Sauaia, A | 1 |
| Yaffe, MB | 1 |
| Liu, C | 3 |
| Lin, Y | 1 |
| Dong, Y | 1 |
| Wu, Y | 1 |
| Bao, Y | 1 |
| Yan, H | 2 |
| Ma, J | 1 |
| Fernández-Cuadros, ME | 1 |
| Albaladejo-Florín, MJ | 1 |
| Álava-Rabasa, S | 1 |
| Usandizaga-Elio, I | 1 |
| Martinez-Quintanilla Jimenez, D | 1 |
| Peña-Lora, D | 1 |
| Neira-Borrajo, I | 1 |
| López-Muñoz, MJ | 1 |
| Rodríguez-de-Cía, J | 1 |
| Pérez-Moro, OS | 1 |
| Abdallah, M | 1 |
| Alsaleh, H | 1 |
| Baradwan, A | 1 |
| Alfawares, R | 1 |
| Alobaid, A | 1 |
| Rasheed, A | 1 |
| Soliman, I | 1 |
| Wendel Garcia, PD | 1 |
| Fumeaux, T | 1 |
| Guerci, P | 1 |
| Heuberger, DM | 1 |
| Montomoli, J | 2 |
| Roche-Campo, F | 1 |
| Schuepbach, RA | 1 |
| Hilty, MP | 1 |
| Poloni, TE | 1 |
| Carlos, AF | 1 |
| Cairati, M | 1 |
| Cutaia, C | 1 |
| Medici, V | 1 |
| Marelli, E | 1 |
| Ferrari, D | 1 |
| Galli, A | 1 |
| Bognetti, P | 1 |
| Davin, A | 1 |
| Cirrincione, A | 1 |
| Ceretti, A | 1 |
| Cereda, C | 1 |
| Ceroni, M | 1 |
| Tronconi, L | 1 |
| Vitali, S | 1 |
| Guaita, A | 1 |
| Leeds, JS | 1 |
| Raviprakash, V | 1 |
| Jacques, T | 1 |
| Scanlon, N | 1 |
| Cundall, J | 1 |
| Leeds, CM | 1 |
| Riva, A | 1 |
| Gray, EH | 1 |
| Azarian, S | 1 |
| Zamalloa, A | 1 |
| McPhail, MJW | 1 |
| Vincent, RP | 1 |
| Williams, R | 1 |
| Chokshi, S | 1 |
| Patel, VC | 1 |
| Edwards, LA | 1 |
| Alqarawi, W | 1 |
| Birnie, DH | 1 |
| Golian, M | 1 |
| Nair, GM | 1 |
| Nery, PB | 1 |
| Klein, A | 1 |
| Davis, DR | 1 |
| Sadek, MM | 1 |
| Neilipovitz, D | 1 |
| Johnson, CB | 1 |
| Green, MS | 1 |
| Redpath, C | 1 |
| Miller, DC | 1 |
| Beamer, P | 1 |
| Billheimer, D | 1 |
| Subbian, V | 1 |
| Sorooshian, A | 1 |
| Campbell, BS | 1 |
| Mosier, JM | 1 |
| Novaretti, JV | 1 |
| Astur, DC | 1 |
| Cavalcante, ELB | 1 |
| Kaleka, CC | 1 |
| Amaro, JT | 1 |
| Cohen, M | 1 |
| Huang, W | 1 |
| Li, T | 1 |
| Ling, Y | 1 |
| Qian, ZP | 1 |
| Zhang, YY | 1 |
| Huang, D | 1 |
| Xu, SB | 1 |
| Liu, XH | 1 |
| Xia, L | 1 |
| Yang, Y | 3 |
| Lu, SH | 1 |
| Lu, HZ | 1 |
| Zhang, R | 2 |
| Ma, JX | 1 |
| Tang, S | 1 |
| Li, CM | 1 |
| Wan, J | 1 |
| Wang, JF | 1 |
| Ma, JQ | 1 |
| Luo, JJ | 1 |
| Chen, HY | 2 |
| Mi, SL | 1 |
| Chen, SY | 1 |
| Su, YG | 1 |
| Ge, JB | 1 |
| Milheiro, SA | 1 |
| Gonçalves, J | 1 |
| Lopes, RMRM | 1 |
| Madureira, M | 1 |
| Lobo, L | 1 |
| Lopes, A | 1 |
| Nogueira, F | 1 |
| Fontinha, D | 1 |
| Prudêncio, M | 1 |
| M Piedade, MF | 1 |
| Pinto, SN | 1 |
| Florindo, PR | 1 |
| Moreira, R | 1 |
| Castillo-Lora, J | 1 |
| Delley, MF | 1 |
| Laga, SM | 1 |
| Mayer, JM | 1 |
| Sutjarit, N | 1 |
| Thongon, N | 1 |
| Weerachayaphorn, J | 1 |
| Piyachaturawat, P | 1 |
| Suksamrarn, A | 1 |
| Suksen, K | 1 |
| Papachristou, DJ | 1 |
| Blair, HC | 1 |
| Hu, Y | 2 |
| Shen, P | 1 |
| Zeng, N | 1 |
| Wang, L | 3 |
| Yan, D | 1 |
| Cui, L | 1 |
| Yang, K | 2 |
| Zhai, C | 1 |
| Yang, M | 1 |
| Lao, X | 1 |
| Sun, J | 1 |
| Ma, N | 1 |
| Ye, W | 1 |
| Guo, P | 1 |
| Rahimi, S | 1 |
| Singh, MP | 1 |
| Gupta, J | 1 |
| Nakanishi, I | 1 |
| Ohkubo, K | 1 |
| Shoji, Y | 1 |
| Fujitaka, Y | 1 |
| Shimoda, K | 1 |
| Matsumoto, KI | 1 |
| Fukuhara, K | 1 |
| Hamada, H | 1 |
| van der Boom, T | 1 |
| Gruppen, EG | 1 |
| Lefrandt, JD | 1 |
| Connelly, MA | 1 |
| Links, TP | 1 |
| Dullaart, RPF | 1 |
| Berry, JD | 1 |
| Bedlack, R | 1 |
| Mathews, D | 1 |
| Agnese, W | 1 |
| Apple, S | 1 |
| Meloncelli, S | 1 |
| Divizia, M | 1 |
| Germani, G | 1 |
| Adefegha, SA | 1 |
| Bottari, NB | 1 |
| Leal, DB | 1 |
| de Andrade, CM | 1 |
| Schetinger, MR | 1 |
| Martínez-Velasco, A | 1 |
| Perez-Ortiz, AC | 1 |
| Antonio-Aguirre, B | 1 |
| Martínez-Villaseñor, L | 1 |
| Lira-Romero, E | 1 |
| Palacio-Pastrana, C | 1 |
| Zenteno, JC | 1 |
| Ramirez, I | 1 |
| Zepeda-Palacio, C | 1 |
| Mendoza-Velásquez, C | 1 |
| Camacho-Ordóñez, A | 1 |
| Ortiz Bibriesca, DM | 1 |
| Estrada-Mena, FJ | 1 |
| Martin, BL | 1 |
| Thompson, LC | 1 |
| Kim, YH | 2 |
| Snow, SJ | 1 |
| Schladweiler, MC | 1 |
| Phillips, P | 1 |
| Harmon, M | 1 |
| King, C | 1 |
| Richards, J | 1 |
| George, I | 1 |
| Haykal-Coates, N | 1 |
| Gilmour, MI | 1 |
| Kodavanti, UP | 1 |
| Hazari, MS | 1 |
| Farraj, AK | 1 |
| Shen, Z | 1 |
| Zou, Y | 1 |
| Gao, K | 1 |
| Lazar, S | 1 |
| Wurtzel, JGT | 1 |
| Ma, P | 1 |
| Goldfinger, LE | 1 |
| Vukelic, M | 1 |
| Laloo, A | 1 |
| Kyttaris, VC | 1 |
| Chen, R | 1 |
| Xun, J | 1 |
| Hu, Z | 1 |
| Huang, Q | 2 |
| Steinhart, C | 1 |
| Shen, Y | 1 |
| Lu, H | 1 |
| Mansuri, A | 1 |
| Lokhande, K | 1 |
| Kore, S | 1 |
| Gaikwad, S | 1 |
| Nawani, N | 1 |
| Swamy, KV | 1 |
| Junnarkar, M | 1 |
| Pawar, S | 1 |
| Shaheen, MY | 1 |
| Basudan, AM | 1 |
| Niazy, AA | 1 |
| van den Beucken, JJJP | 1 |
| Jansen, JA | 1 |
| Alghamdi, HS | 1 |
| Gao, Q | 2 |
| Guo, X | 1 |
| Cao, Y | 1 |
| Jia, X | 1 |
| Xu, S | 1 |
| Lu, C | 2 |
| Zhu, H | 2 |
| Melku, M | 1 |
| Abebe, G | 1 |
| Teketel, A | 1 |
| Asrie, F | 1 |
| Yalew, A | 1 |
| Biadgo, B | 1 |
| Kassa, E | 1 |
| Damtie, D | 1 |
| Anlay, DZ | 1 |
| Ahmed, MFE | 1 |
| Ramadan, H | 1 |
| Seinige, D | 1 |
| Kehrenberg, C | 1 |
| Abd El-Wahab, A | 1 |
| Volkmann, N | 1 |
| Kemper, N | 1 |
| Schulz, J | 1 |
| Hu, MY | 1 |
| Wu, YN | 1 |
| McEvoy, MP | 1 |
| Wang, YF | 1 |
| Cong, WL | 1 |
| Liu, LP | 1 |
| Li, XX | 1 |
| Zhou, CL | 1 |
| Chen, WM | 1 |
| Wei, KL | 1 |
| Tung, SY | 1 |
| Shen, CH | 1 |
| Chang, TS | 1 |
| Yen, CW | 1 |
| Hsieh, YY | 1 |
| Chiu, WN | 1 |
| Hu, JH | 1 |
| Lu, SN | 1 |
| Hung, CH | 1 |
| Alakavuklar, MA | 1 |
| Fuqua, C | 1 |
| Luo, KL | 1 |
| Underwood, RS | 1 |
| Greenwald, I | 1 |
| Elashiry, MM | 1 |
| Elashiry, M | 1 |
| Zeitoun, R | 1 |
| Elsayed, R | 1 |
| Tian, F | 1 |
| Saber, SE | 1 |
| Elashry, SH | 1 |
| Tay, FR | 1 |
| Cutler, CW | 1 |
| O'Dowd, A | 1 |
| Maciel, M | 1 |
| Poole, ST | 1 |
| Jobling, MG | 1 |
| Rollenhagen, JE | 1 |
| Woods, CM | 1 |
| Sincock, SA | 1 |
| McVeigh, AL | 1 |
| Gregory, MJ | 1 |
| Maves, RC | 1 |
| Prouty, MG | 1 |
| Holmes, RK | 1 |
| Savarino, SJ | 1 |
| Mor, MK | 1 |
| Palevsky, PM | 5 |
| Kaufman, JS | 1 |
| Thiessen Philbrook, H | 1 |
| Weisbord, SD | 1 |
| Parikh, CR | 1 |
| John, CM | 1 |
| Phillips, NJ | 1 |
| Jarvis, GA | 1 |
| Kilburn, S | 1 |
| Kapoor, M | 1 |
| Chaturvedi, S | 1 |
| Shaw, KJ | 1 |
| Chaturvedi, V | 1 |
| Kong, X | 1 |
| Zhang, T | 1 |
| Xiao, H | 1 |
| Feng, X | 1 |
| Tu, H | 1 |
| Feng, J | 1 |
| Sabet, M | 1 |
| Tarazi, Z | 1 |
| Griffith, DC | 1 |
| Nguyen, F | 1 |
| Guan, P | 1 |
| Guerrero, DT | 1 |
| Kolla, V | 1 |
| Naraparaju, K | 1 |
| Perry, LM | 1 |
| Soberman, D | 1 |
| Pressly, BB | 1 |
| Alferiev, IS | 1 |
| Chorny, M | 1 |
| Brodeur, GM | 1 |
| Gao, X | 2 |
| Cheng, YH | 1 |
| Enten, GA | 1 |
| DeSantis, AJ | 1 |
| Gaponenko, V | 1 |
| Majetschak, M | 1 |
| Kim, DY | 1 |
| Choi, MJ | 1 |
| Ko, TK | 1 |
| Lee, NH | 1 |
| Kim, OH | 1 |
| Cheon, HG | 1 |
| Cai, H | 1 |
| Yip, V | 1 |
| Lee, MV | 1 |
| Wong, S | 1 |
| Saad, O | 1 |
| Ma, S | 1 |
| Ljumanovic, N | 1 |
| Khojasteh, SC | 1 |
| Kamath, AV | 1 |
| Shen, BQ | 1 |
| Cuypers, ML | 1 |
| Chanteux, H | 1 |
| Gillent, E | 1 |
| Bonnaillie, P | 1 |
| Saunders, K | 1 |
| Beckers, C | 1 |
| Delatour, C | 1 |
| Dell'Aiera, S | 1 |
| Ungell, AL | 1 |
| Nicolaï, J | 1 |
| Knapp, AK | 1 |
| Chen, A | 1 |
| Griffin-Nolan, RJ | 1 |
| Baur, LE | 1 |
| Carroll, CJW | 1 |
| Gray, JE | 1 |
| Hoffman, AM | 1 |
| Li, X | 4 |
| Post, AK | 1 |
| Slette, IJ | 1 |
| Collins, SL | 1 |
| Luo, Y | 1 |
| Smith, MD | 1 |
| Temitayo, GI | 1 |
| Olawande, B | 1 |
| Emmanuel, YO | 1 |
| Timothy, AT | 1 |
| Kehinde, O | 1 |
| Susan, LF | 1 |
| Ezra, L | 1 |
| Joseph, OO | 1 |
| Lev, S | 1 |
| Desmarini, D | 1 |
| Liuwantara, D | 1 |
| Sorrell, TC | 1 |
| Hawthorne, WJ | 1 |
| Djordjevic, JT | 1 |
| Verso, MG | 1 |
| Costantino, C | 1 |
| Marrella, A | 1 |
| Immordino, P | 1 |
| Vitale, F | 1 |
| Amodio, E | 1 |
| Wang, YD | 1 |
| Yao, WL | 1 |
| Xin, ZM | 1 |
| Han, TT | 1 |
| Wang, ZG | 1 |
| Chen, L | 1 |
| Cai, C | 1 |
| Zhang, Y | 4 |
| Ba, D | 1 |
| Wen, S | 1 |
| Tian, Q | 1 |
| Lv, W | 1 |
| Cheng, G | 1 |
| Li, N | 1 |
| Yue, XY | 1 |
| Chu, WJ | 1 |
| Chen, Q | 1 |
| Choi, ES | 1 |
| Zhao, X | 3 |
| Zhou, HD | 1 |
| Sun, XF | 1 |
| Sharma, S | 2 |
| Chhoker, S | 1 |
| Xie, C | 1 |
| Ong, EWY | 1 |
| Tan, ZK | 1 |
| Evans, S | 1 |
| Weinheimer, CJ | 1 |
| Kovacs, A | 1 |
| Williams, JW | 1 |
| Randolph, GJ | 1 |
| Jiang, W | 1 |
| Barger, PM | 1 |
| Mann, DL | 1 |
| Liu, J | 2 |
| Huang, Y | 1 |
| Kong, L | 1 |
| Yu, X | 1 |
| Feng, B | 1 |
| Liu, D | 1 |
| Zhao, B | 1 |
| Mendes, GC | 1 |
| Yuan, P | 1 |
| Ge, D | 1 |
| Wang, WM | 1 |
| Fontes, EPB | 1 |
| Li, P | 1 |
| Shan, L | 1 |
| He, P | 1 |
| Katoh, T | 1 |
| Sengoku, T | 1 |
| Hirata, K | 1 |
| Ogata, K | 1 |
| Suga, H | 1 |
| Shun, C | 1 |
| Yong-Yi, J | 1 |
| Mei-Li, C | 1 |
| Shi-Li, L | 1 |
| Jian-Bo, Z | 1 |
| Dan-Li, W | 1 |
| Zhi-Min, G | 1 |
| Ibrahim, AM | 1 |
| Zakhary, SY | 1 |
| Amin, SAW | 1 |
| Ugurlu, M | 1 |
| Fornari, VJ | 1 |
| Hartmann, MSM | 1 |
| Vanni, JR | 1 |
| Rodriguez, R | 1 |
| Langaro, MC | 1 |
| Pelepenko, LE | 1 |
| Zaia, AA | 1 |
| Nakanjako, D | 1 |
| Zalwango, F | 1 |
| Wairagala, P | 1 |
| Luboga, F | 1 |
| Andia Biraro, I | 1 |
| Bukirwa, VD | 1 |
| Mboowa, MG | 1 |
| Cose, S | 1 |
| Seeley, J | 1 |
| Elliott, A | 1 |
| Zhao, G | 1 |
| Sun, P | 1 |
| Hao, S | 1 |
| Wang, X | 1 |
| Qu, G | 1 |
| Xing, Y | 1 |
| Xu, X | 1 |
| Maierhofer, M | 1 |
| Rieger, V | 1 |
| Mayr, T | 1 |
| Liu, Y | 2 |
| Zhang, Q | 1 |
| Bigliardi, AP | 1 |
| Fernandes, CLF | 1 |
| Pinto, EA | 1 |
| Dos Santos, M | 1 |
| Garcia, EM | 1 |
| Baisch, PRM | 1 |
| Soares, MCF | 1 |
| Muccillo-Baisch, AL | 1 |
| da Silva Júnior, FMR | 1 |
| Yu, W | 1 |
| Ju, C | 1 |
| Wang, K | 1 |
| Zheng, Z | 1 |
| Liu, H | 1 |
| Gao, Y | 1 |
| Martínez-Navarro, EM | 1 |
| Cebrián-Tarancón, C | 1 |
| Moratalla-López, N | 1 |
| Lorenzo, C | 1 |
| Alonso, GL | 1 |
| Salinas, RM | 1 |
| Bermúdez de Castro, JM | 1 |
| Modesto-Mata, M | 1 |
| Martín-Francés, L | 1 |
| García-Campos, C | 1 |
| Martínez de Pinillos, M | 1 |
| Martinón-Torres, M | 1 |
| Hasani, M | 1 |
| Wu, F | 2 |
| Warriner, K | 1 |
| Kurz, M | 1 |
| Gretzke, D | 1 |
| Hörlein, R | 1 |
| Turpault, S | 1 |
| Atzrodt, J | 1 |
| Derdau, V | 1 |
| Yao, Y | 1 |
| Ou, X | 1 |
| Zhao, S | 1 |
| Tian, B | 1 |
| Jin, S | 1 |
| Jiang, Z | 1 |
| Zhou, Z | 1 |
| Liu, M | 2 |
| Jiang, GD | 1 |
| Mou, LH | 1 |
| Chen, JJ | 1 |
| Li, ZY | 1 |
| He, SG | 1 |
| Reale, E | 1 |
| Fustinoni, S | 1 |
| Mercadante, R | 1 |
| Polledri, E | 1 |
| Hopf, NB | 1 |
| Grant, PC | 1 |
| Levy, K | 1 |
| Lattimer, TA | 1 |
| Depner, RM | 1 |
| Kerr, CW | 1 |
| Sato, J | 1 |
| Merenda, MEZ | 1 |
| Uemoto, AT | 1 |
| Dos Santos, MP | 1 |
| Barion, MRL | 1 |
| Carciofi, AC | 1 |
| de Paula Dorigam, JC | 1 |
| Ribeiro, LB | 1 |
| Vasconcellos, RS | 1 |
| Waller, SB | 1 |
| Peter, CM | 1 |
| Hoffmann, JF | 1 |
| Cleff, MB | 1 |
| Faria de, RO | 1 |
| Zani, JL | 1 |
| Martins, BA | 1 |
| Sande, D | 1 |
| Solares, MD | 1 |
| Takahashi, JA | 1 |
| Yang, S | 2 |
| Jia, Y | 1 |
| Yin, C | 1 |
| Zhao, R | 1 |
| Ojha, M | 1 |
| Wu, B | 1 |
| Deepa, M | 1 |
| Mo, J | 1 |
| Au, DW | 1 |
| Wan, MT | 1 |
| Shi, J | 1 |
| Zhang, G | 1 |
| Winkler, C | 1 |
| Kong, RY | 1 |
| Seemann, F | 1 |
| Bianco, M | 1 |
| Calvano, CD | 1 |
| Ventura, G | 1 |
| Bianco, G | 1 |
| Losito, I | 1 |
| Cataldi, TRI | 1 |
| Angiolella, L | 1 |
| Staudt, A | 1 |
| Duarte, PF | 1 |
| Amaral, BPD | 1 |
| Peixoto Andrade, BCO | 1 |
| Simas, NK | 1 |
| Correa Ramos Leal, I | 1 |
| Sangenito, LS | 1 |
| Santos, ALSD | 1 |
| de Oliveira, D | 1 |
| Junges, A | 1 |
| Cansian, RL | 1 |
| Paroul, N | 1 |
| Siu, J | 1 |
| Klingler, L | 1 |
| Hung, CT | 1 |
| Jeong, SH | 1 |
| Smith, S | 1 |
| Tingle, MD | 1 |
| Wagner Mackenzie, B | 1 |
| Biswas, K | 1 |
| Douglas, RG | 1 |
| Oza, AM | 1 |
| Lorusso, D | 1 |
| Aghajanian, C | 1 |
| Oaknin, A | 1 |
| Dean, A | 1 |
| Colombo, N | 1 |
| Weberpals, JI | 1 |
| Clamp, AR | 1 |
| Scambia, G | 1 |
| Leary, A | 1 |
| Holloway, RW | 1 |
| Gancedo, MA | 1 |
| Fong, PC | 1 |
| Goh, JC | 1 |
| O'Malley, DM | 1 |
| Armstrong, DK | 1 |
| Banerjee, S | 1 |
| García-Donas, J | 1 |
| Swisher, EM | 1 |
| Cella, D | 1 |
| Meunier, J | 1 |
| Goble, S | 1 |
| Cameron, T | 1 |
| Maloney, L | 1 |
| Mörk, AC | 1 |
| Bedel, J | 1 |
| Ledermann, JA | 1 |
| Coleman, RL | 1 |
| Vlek, SL | 1 |
| Burm, R | 1 |
| Govers, TM | 1 |
| Vleugels, MPH | 1 |
| Tuynman, JB | 1 |
| Mijatovic, V | 1 |
| Leicht, AS | 1 |
| Connor, J | 1 |
| Conduit, N | 1 |
| Vaquera, A | 1 |
| Gómez, MA | 1 |
| McKay, JA | 1 |
| Church, AL | 1 |
| Rubin, N | 1 |
| Emory, TH | 1 |
| Hoven, NF | 1 |
| Kuehn-Hajder, JE | 1 |
| Nelson, MT | 1 |
| Ramanna, S | 1 |
| Auerbach, EJ | 1 |
| Moeller, S | 1 |
| Bolan, PJ | 1 |
| Fox, NP | 1 |
| Leonard, M | 1 |
| Sjerps, MJ | 1 |
| Chang, EF | 1 |
| Hyun, S | 1 |
| Saejio, A | 1 |
| Shanmugam, S | 1 |
| Liu, X | 1 |
| Sun, M | 1 |
| Bai, Z | 1 |
| Jaque-Fernandez, F | 1 |
| Beaulant, A | 1 |
| Berthier, C | 1 |
| Monteiro, L | 1 |
| Allard, B | 1 |
| Casas, M | 1 |
| Rieusset, J | 1 |
| Jacquemond, V | 1 |
| Góngora-García, OR | 1 |
| Aca-Aca, G | 1 |
| Baz-Rodríguez, SA | 1 |
| Monte, A | 1 |
| Maganaris, C | 1 |
| Baltzopoulos, V | 1 |
| Zamparo, P | 1 |
| Wang, Z | 2 |
| Hou, Y | 1 |
| Cai, L | 1 |
| Tu, YJ | 1 |
| Tan, B | 1 |
| Jiang, L | 1 |
| Wu, ZH | 1 |
| Yu, HJ | 1 |
| Li, XQ | 1 |
| Yang, AD | 1 |
| Titze, IR | 1 |
| Palaparthi, A | 1 |
| Mau, T | 1 |
| González, MA | 1 |
| Goiri, F | 1 |
| Barandika, JF | 1 |
| García-Pérez, AL | 1 |
| Jatt, LP | 1 |
| Gandhi, MM | 1 |
| Guo, R | 1 |
| Sukhija-Cohen, A | 1 |
| Bhattacharya, D | 1 |
| Tseng, CH | 1 |
| Chew, KW | 1 |
| Onwumere, J | 1 |
| Pia Tek, J | 1 |
| Budnyak, T | 1 |
| Budnyk, S | 1 |
| Karim, Z | 1 |
| Thersleff, T | 1 |
| Kuśtrowski, P | 1 |
| Mathew, AP | 1 |
| Slabon, A | 1 |
| Guo, M | 1 |
| Zhao, T | 1 |
| Xing, Z | 1 |
| Qiu, Y | 1 |
| Pan, K | 1 |
| Li, Z | 2 |
| Zhou, W | 1 |
| Ghassemi Tabrizi, S | 1 |
| Arbuznikov, AV | 1 |
| Jiménez-Hoyos, CA | 1 |
| Kaupp, M | 1 |
| Lin, MH | 2 |
| Bulman, DM | 1 |
| Remucal, CK | 1 |
| Chaplin, BP | 1 |
| Laguerre, A | 1 |
| George, LA | 1 |
| Gall, ET | 1 |
| Emerson, MS | 1 |
| Maginn, EJ | 1 |
| Margulis, CJ | 1 |
| Li, H | 2 |
| Feng, W | 1 |
| Kang, X | 2 |
| Yan, S | 1 |
| Chao, M | 1 |
| Mo, S | 1 |
| Sun, W | 1 |
| Lu, Y | 1 |
| Chen, C | 1 |
| Stevens, DM | 1 |
| Adiseshaiah, P | 1 |
| Dasa, SSK | 1 |
| Potter, TM | 1 |
| Skoczen, SL | 1 |
| Snapp, KS | 1 |
| Cedrone, E | 1 |
| Busman-Sahay, K | 1 |
| Rosen, EP | 1 |
| Sykes, C | 1 |
| Cottrell, M | 1 |
| Dobrovolskaia, MA | 1 |
| Estes, JD | 1 |
| Kashuba, ADM | 1 |
| Stern, ST | 1 |
| Özütemiz, C | 1 |
| Neil, EC | 1 |
| Tanwar, M | 1 |
| Rubin, NT | 1 |
| Ozturk, K | 1 |
| Cayci, Z | 1 |
| Duscha, BD | 1 |
| Kraus, WE | 1 |
| Jones, WS | 1 |
| Robbins, JL | 1 |
| Piner, LW | 1 |
| Huffman, KM | 1 |
| Allen, JD | 1 |
| Annex, BH | 1 |
| Mehmood, T | 1 |
| Ahmad, I | 1 |
| Bibi, S | 1 |
| Mustafa, B | 1 |
| Ali, I | 1 |
| Dahal, RH | 1 |
| Chaudhary, DK | 1 |
| Kim, DU | 1 |
| Kim, J | 1 |
| Yeter, HH | 1 |
| Gonul, I | 1 |
| Guz, G | 1 |
| Helvaci, O | 1 |
| Korucu, B | 1 |
| Akcay, OF | 1 |
| Derici, U | 1 |
| Arinsoy, T | 1 |
| Neffati, R | 1 |
| Judeinstein, P | 1 |
| Rault, J | 1 |
| Xu, Y | 1 |
| Chai, X | 1 |
| Ren, T | 1 |
| Yu, S | 1 |
| Fu, Q | 2 |
| Ye, J | 1 |
| Ge, X | 1 |
| Song, J | 1 |
| Yang, H | 2 |
| El-Baba, TJ | 1 |
| Lutomski, CA | 1 |
| Kantsadi, AL | 1 |
| Malla, TR | 1 |
| John, T | 1 |
| Mikhailov, V | 1 |
| Bolla, JR | 1 |
| Schofield, CJ | 1 |
| Zitzmann, N | 1 |
| Vakonakis, I | 1 |
| Robinson, CV | 1 |
| Langham, MC | 1 |
| Caporale, AS | 1 |
| Wehrli, FW | 1 |
| Parry, S | 1 |
| Schwartz, N | 1 |
| den Boer, RB | 1 |
| Jones, KI | 1 |
| Ash, S | 1 |
| van Boxel, GI | 1 |
| Gillies, RS | 1 |
| O'Donnell, T | 1 |
| Ruurda, JP | 1 |
| Sgromo, B | 1 |
| Silva, MA | 1 |
| Maynard, ND | 1 |
| Sivieri, EM | 1 |
| Eichenwald, EC | 1 |
| Rub, D | 1 |
| Abbasi, S | 1 |
| Krahnert, I | 1 |
| Bolze, A | 1 |
| Gibon, Y | 1 |
| Fernie, AR | 1 |
| Huang, L | 1 |
| Wan, Y | 1 |
| Dang, Z | 1 |
| Yang, P | 1 |
| Yang, Q | 1 |
| Wu, S | 2 |
| Lin, CC | 1 |
| Hsu, CT | 1 |
| Liu, W | 2 |
| Huang, SC | 1 |
| Kortz, U | 1 |
| Mougharbel, AS | 1 |
| Chen, TY | 1 |
| Hu, CW | 1 |
| Lee, JF | 1 |
| Wang, CC | 1 |
| Liao, YF | 1 |
| Li, LJ | 1 |
| Li, L | 1 |
| Peng, S | 1 |
| Stimming, U | 1 |
| Hebbar Kannur, K | 1 |
| Yaqub, TB | 1 |
| Pupier, C | 1 |
| Héau, C | 1 |
| Cavaleiro, A | 1 |
| Yamamoto, S | 1 |
| Ono, A | 1 |
| Matsui, J | 1 |
| Hoshino, N | 1 |
| Akutagawa, T | 1 |
| Miyashita, T | 1 |
| Mitsuishi, M | 1 |
| Patel, SM | 1 |
| Smith, TG | 1 |
| Morton, M | 1 |
| Stiers, KM | 1 |
| Seravalli, J | 1 |
| Mayclin, SJ | 1 |
| Edwards, TE | 1 |
| Tanner, JJ | 1 |
| Becker, DF | 1 |
| Butcher, TW | 1 |
| Yang, JL | 1 |
| Hartwig, JF | 1 |
| Yu, MF | 1 |
| Xia, ZZ | 1 |
| Yao, JC | 1 |
| Feng, Z | 1 |
| Li, DH | 1 |
| Liu, T | 1 |
| Cheng, GJ | 1 |
| He, DL | 1 |
| Li, XH | 1 |
| Huurman, R | 1 |
| Schinkel, AFL | 1 |
| de Jong, PL | 1 |
| van Slegtenhorst, MA | 1 |
| Hirsch, A | 1 |
| Michels, M | 1 |
| Kataja, A | 1 |
| Tarvasmäki, T | 1 |
| Lassus, J | 1 |
| Sionis, A | 1 |
| Mebazaa, A | 1 |
| Pulkki, K | 1 |
| Banaszewski, M | 1 |
| Carubelli, V | 1 |
| Hongisto, M | 1 |
| Jankowska, E | 1 |
| Jurkko, R | 1 |
| Jäntti, T | 1 |
| Kasztura, M | 1 |
| Parissis, J | 1 |
| Sabell, T | 1 |
| Silva-Cardoso, J | 1 |
| Spinar, J | 1 |
| Tolppanen, H | 1 |
| Harjola, VP | 1 |
| Carsetti, A | 1 |
| Damiani, E | 1 |
| Casarotta, E | 1 |
| Scorcella, C | 1 |
| Domizi, R | 1 |
| Gasparri, F | 1 |
| Gabbanelli, V | 1 |
| Pantanetti, S | 1 |
| Carozza, R | 1 |
| Adrario, E | 1 |
| Donati, A | 1 |
| Almada, E | 1 |
| Pariani, A | 1 |
| Rivabella Maknis, T | 1 |
| Hidalgo, F | 1 |
| Vena, R | 1 |
| Favre, C | 1 |
| Larocca, MC | 1 |
| Lu, ZY | 1 |
| Jiang, WD | 1 |
| Wu, P | 1 |
| Kuang, SY | 1 |
| Tang, L | 1 |
| Yang, J | 1 |
| Zhou, XQ | 1 |
| Feng, L | 1 |
| Leal, M | 1 |
| Zampini, IC | 1 |
| Mercado, MI | 1 |
| Moreno, MA | 1 |
| Simirgiotis, MJ | 1 |
| Bórquez, J | 1 |
| Ponessa, G | 1 |
| Isla, MI | 1 |
| Saliu, IO | 1 |
| Amoo, ZA | 1 |
| Khan, MF | 1 |
| Olaleye, MT | 1 |
| Rema, V | 1 |
| Akinmoladun, AC | 1 |
| Khan, AU | 1 |
| Rahman, AU | 1 |
| Yuan, Q | 1 |
| Ahmad, A | 1 |
| Khan, ZUH | 1 |
| Mahnashi, MH | 1 |
| Alyami, BA | 1 |
| Alqahtani, YS | 1 |
| Ullah, S | 1 |
| Wirman, AP | 1 |
| Gao, M | 1 |
| Deng, L | 1 |
| Zhang, K | 1 |
| Xia, Z | 1 |
| Gao, D | 1 |
| Balkissou, AD | 1 |
| Poka-Mayap, V | 1 |
| Massongo, M | 1 |
| Djenabou, A | 1 |
| Endale-Mangamba, LM | 1 |
| Olomo, EJ | 1 |
| Boulleys-Nana, JR | 1 |
| Diffo-Sonkoue, L | 1 |
| Adidigue-Ndiome, R | 1 |
| Alexandra, AJE | 1 |
| Haman-Wabi, AB | 1 |
| Adama, S | 1 |
| Iddi-Faical, A | 1 |
| Pefura-Yone, EW | 1 |
| Zhao, Q | 1 |
| Tong, W | 1 |
| Ge, C | 1 |
| Zhao, D | 1 |
| Norbäck, D | 1 |
| Li, B | 1 |
| Zhao, Z | 1 |
| Huang, C | 1 |
| Zhang, X | 1 |
| Qian, H | 1 |
| Yang, X | 1 |
| Sun, Y | 1 |
| Sundell, J | 1 |
| Deng, Q | 1 |
| Kim, HJ | 1 |
| Jeon, JW | 1 |
| Hwang, SM | 1 |
| Chu, KI | 1 |
| Cha, YH | 1 |
| Kwak, YD | 1 |
| Choi, SD | 1 |
| Aslam, M | 1 |
| Kim, CG | 1 |
| Zhou, J | 1 |
| Yang, E | 1 |
| Yang, W | 1 |
| Uchiyama, H | 1 |
| Tsujimoto, M | 2 |
| Shimada, N | 2 |
| Tsutsui, K | 1 |
| Nitta, A | 1 |
| Yoshida, T | 1 |
| Furukubo, T | 2 |
| Izumi, S | 2 |
| Yamakawa, T | 2 |
| Tachiki, H | 1 |
| Minegaki, T | 1 |
| Nishiguchi, K | 2 |
| Chen, G | 1 |
| Dong, QR | 1 |
| Li, MX | 1 |
| Li, XM | 1 |
| Issa, N | 1 |
| Ortiz, F | 1 |
| Reule, SA | 1 |
| Kukla, A | 1 |
| Kasiske, BL | 1 |
| Mauer, M | 1 |
| Jackson, S | 1 |
| Matas, AJ | 1 |
| Ibrahim, HN | 1 |
| Najafian, B | 1 |
| Fried, LF | 4 |
| Emanuele, N | 3 |
| Zhang, JH | 4 |
| Brophy, M | 2 |
| Conner, TA | 1 |
| Duckworth, W | 2 |
| Leehey, DJ | 2 |
| McCullough, PA | 2 |
| O'Connor, T | 2 |
| Reilly, RF | 2 |
| Seliger, SL | 2 |
| Warren, SR | 2 |
| Watnick, S | 1 |
| Peduzzi, P | 2 |
| Guarino, P | 2 |
| Lambers Heerspink, HJ | 4 |
| Weldegiorgis, M | 1 |
| Inker, LA | 1 |
| Gansevoort, R | 1 |
| Parving, HH | 4 |
| Dwyer, JP | 1 |
| Mondal, H | 1 |
| Coresh, J | 1 |
| Greene, T | 1 |
| Levey, AS | 1 |
| de Zeeuw, D | 10 |
| Riphagen, IJ | 1 |
| Deetman, PE | 1 |
| Bakker, SJ | 2 |
| Navis, G | 3 |
| Cooper, ME | 6 |
| Lewis, JB | 2 |
| Schievink, B | 1 |
| Rossing, P | 1 |
| Schutte, E | 1 |
| Lutgers, HL | 1 |
| Vart, P | 1 |
| Wolffenbuttel, BH | 1 |
| Umanath, K | 1 |
| Gansevoort, RT | 2 |
| Nair, AR | 1 |
| Ebenezer, PJ | 1 |
| Saini, Y | 1 |
| Francis, J | 1 |
| Emanuele, NV | 1 |
| Whaley-Connell, A | 1 |
| Felix Kröpelin, T | 1 |
| Holtkamp, FA | 1 |
| Packham, DK | 1 |
| L Heerspink, HJ | 1 |
| Hatch, M | 4 |
| Freel, RW | 4 |
| Suzuki, H | 6 |
| Kanno, Y | 3 |
| Sugahara, S | 1 |
| Ikeda, N | 1 |
| Shoda, J | 1 |
| Takenaka, T | 2 |
| Inoue, T | 1 |
| Araki, R | 1 |
| Huang, GD | 1 |
| Seliger, S | 1 |
| Guo, LL | 1 |
| Pan, Y | 2 |
| Jin, HM | 2 |
| Marshall, SM | 1 |
| Desbuards, N | 1 |
| Hyvelin, JM | 1 |
| Machet, MC | 1 |
| Eder, V | 1 |
| Garrigue, MA | 1 |
| Halimi, JM | 1 |
| Antier, D | 1 |
| Joy, MS | 1 |
| Dornbrook-Lavender, K | 1 |
| Blaisdell, J | 1 |
| Hilliard, T | 1 |
| Boyette, T | 1 |
| Hogan, SL | 1 |
| Candiani, C | 1 |
| Falk, RJ | 1 |
| Goldstein, JA | 1 |
| González F, F | 1 |
| Fuentes C, V | 1 |
| Castro H, C | 1 |
| Santelices L, JP | 1 |
| Lorca H, E | 1 |
| Seeman, T | 1 |
| Pohl, M | 1 |
| Misselwitz, J | 1 |
| John, U | 1 |
| Woo, KT | 1 |
| Wong, KS | 2 |
| Chan, CM | 1 |
| Higuchi, K | 1 |
| Shima, D | 1 |
| Yokota, H | 1 |
| Otagiri, M | 1 |
| Hirata, S | 1 |
| Takara, K | 1 |
| Kujal, P | 1 |
| Chábová, VČ | 1 |
| Vernerová, Z | 1 |
| Walkowska, A | 1 |
| Kompanowska-Jezierska, E | 1 |
| Sadowski, J | 1 |
| Vaňourková, Z | 1 |
| Husková, Z | 1 |
| Opočenský, M | 1 |
| Skaroupková, P | 1 |
| Schejbalová, S | 1 |
| Kramer, HJ | 1 |
| Rakušan, D | 1 |
| Malý, J | 1 |
| Netuka, I | 1 |
| Vaněčková, I | 1 |
| Kopkan, L | 1 |
| Cervenka, L | 1 |
| Zaki, KS | 1 |
| Majid, U | 1 |
| Islam, N | 1 |
| de Portu, S | 1 |
| Citarella, A | 1 |
| Cammarota, S | 1 |
| Menditto, E | 1 |
| Mantovani, LG | 1 |
| Caletti, MG | 1 |
| Missoni, M | 1 |
| Vezzani, C | 1 |
| Grignoli, M | 1 |
| Piantanida, JJ | 1 |
| Repetto, HA | 1 |
| Exeni, R | 1 |
| Rasse, SM | 1 |
| Reyes, M | 1 |
| Benet, LZ | 1 |
| Lee, YJ | 1 |
| Cho, S | 1 |
| Kim, SR | 1 |
| Jang, HR | 1 |
| Lee, JE | 1 |
| Huh, W | 1 |
| Kim, DJ | 1 |
| Oh, HY | 1 |
| Kim, YG | 1 |
| Ishimitsu, T | 1 |
| Ohno, E | 1 |
| Nakano, N | 1 |
| Furukata, S | 1 |
| Akashiba, A | 1 |
| Minami, J | 1 |
| Numabe, A | 1 |
| Matsuoka, H | 1 |
| Doria, A | 1 |
| Krolewski, AS | 1 |
| Slagman, MC | 1 |
| Waanders, F | 1 |
| Vogt, L | 2 |
| Damman, K | 1 |
| Hemmelder, M | 1 |
| Laverman, GD | 2 |
| Saeed, B | 1 |
| Mazloum, H | 1 |
| Askar, M | 1 |
| Garcia-Touza, M | 1 |
| Sowers, JR | 1 |
| Toba, H | 1 |
| Tojo, C | 1 |
| Noda, K | 1 |
| Kobara, M | 1 |
| Nakata, T | 1 |
| Sun, CY | 1 |
| Chang, SC | 1 |
| Wu, MS | 1 |
| Kayabasi, H | 1 |
| Yilmaz, Z | 1 |
| Sit, D | 1 |
| Kadiroglu, AK | 1 |
| Yilmaz, E | 1 |
| Zhou, XJ | 1 |
| Vaziri, ND | 3 |
| Wang, HW | 1 |
| Wang, XQ | 1 |
| Zanella, MT | 1 |
| Ribeiro, AB | 2 |
| Shibasaki, Y | 3 |
| Nishiue, T | 3 |
| Masaki, H | 3 |
| Matsubara, H | 3 |
| Iwasaka, T | 3 |
| Shahinfar, S | 17 |
| Dickson, TZ | 3 |
| Ahmed, T | 1 |
| Zhang, Z | 13 |
| Ramjit, D | 2 |
| Smith, RD | 1 |
| Brenner, BM | 14 |
| Gerth, WC | 4 |
| Remuzzi, G | 8 |
| Viberti, G | 1 |
| Hannedouche, T | 2 |
| Martinez-Castelao, A | 1 |
| Carides, GW | 7 |
| Brenner, B | 1 |
| Nakayama, M | 1 |
| Tanno, Y | 1 |
| Otsuka, Y | 1 |
| Takahashi, H | 1 |
| Ikeda, M | 1 |
| Katoh, N | 1 |
| Yokoyama, K | 1 |
| Yamamoto, H | 1 |
| Tokutome, G | 1 |
| Hosoya, T | 1 |
| Agarwal, R | 3 |
| Klein, IH | 1 |
| Ligtenberg, G | 1 |
| Oey, PL | 1 |
| Koomans, HA | 1 |
| Blankestijn, PJ | 1 |
| Carswell, CI | 1 |
| Goa, KL | 1 |
| Weidekamm, C | 1 |
| Hauser, P | 1 |
| Hansmann, C | 1 |
| Schwarz, C | 1 |
| Klingler, H | 1 |
| Mayer, G | 1 |
| Oberbauer, R | 1 |
| Herman, WH | 2 |
| Dasbach, EJ | 2 |
| Alexander, CM | 3 |
| Cook, JR | 1 |
| Keane, WF | 10 |
| Lyle, PA | 5 |
| Souchet, T | 1 |
| Durand Zaleski, I | 1 |
| Rodier, M | 1 |
| Gaugris, S | 1 |
| Passa, P | 1 |
| Zukowska-Szczechowska, E | 1 |
| Gosek, K | 1 |
| Grzeszczak, W | 1 |
| Odabas, AR | 1 |
| Cetinkaya, R | 1 |
| Selcuk, Y | 1 |
| Keles, S | 1 |
| Bilen, H | 1 |
| Doggrell, SA | 2 |
| Bakris, GL | 1 |
| Weir, MR | 1 |
| Shanifar, S | 1 |
| Douglas, J | 1 |
| van Dijk, DJ | 1 |
| Appenroth, D | 1 |
| Beutinger, R | 1 |
| Lupp, A | 1 |
| Fleck, C | 1 |
| Postma, MJ | 1 |
| Kruidhof, H | 1 |
| de Jong-van den Berg, LT | 1 |
| Crowe, AV | 1 |
| Howse, M | 1 |
| Vinjamuri, S | 1 |
| Kemp, GJ | 1 |
| Williams, PS | 1 |
| Aunapuu, M | 2 |
| Pechter, U | 2 |
| Arend, A | 1 |
| Suuroja, T | 1 |
| Ots, M | 2 |
| Iino, Y | 2 |
| Hayashi, M | 3 |
| Kawamura, T | 3 |
| Shiigai, T | 2 |
| Tomino, Y | 2 |
| Yamada, K | 2 |
| Kitajima, T | 2 |
| Ideura, T | 2 |
| Koyama, A | 2 |
| Sugisaki, T | 2 |
| Umemura, S | 2 |
| Kawaguchi, Y | 1 |
| Uchida, S | 2 |
| Kuwahara, M | 2 |
| Yamazaki, T | 2 |
| Stoll, ML | 1 |
| Gauthier, BG | 1 |
| Vergara, M | 1 |
| Ramek, J | 1 |
| Frank, R | 1 |
| Trachtman, H | 1 |
| Iñigo, P | 2 |
| Campistol, JM | 3 |
| Saracho, R | 2 |
| Del Castillo, D | 2 |
| Anaya, F | 1 |
| Esforzado, N | 1 |
| Navarro, MD | 1 |
| Oppenheimer, F | 2 |
| Matsuda, H | 1 |
| Hayashi, K | 2 |
| Homma, K | 2 |
| Yoshioka, K | 1 |
| Kanda, T | 1 |
| Takamatsu, I | 1 |
| Tatematsu, S | 1 |
| Wakino, S | 1 |
| Saruta, T | 2 |
| Onuigbo, MA | 1 |
| Ruilope, LM | 1 |
| Segura, J | 1 |
| Rayner, B | 1 |
| Chan, JC | 2 |
| Wat, NM | 1 |
| So, WY | 1 |
| Lam, KS | 1 |
| Chua, CT | 1 |
| Morad, Z | 1 |
| Hille, D | 1 |
| Kurokawa, K | 3 |
| Takamitsu, Y | 1 |
| Kawaguchii, Y | 1 |
| Kööbi, P | 1 |
| Jolma, P | 1 |
| Kalliovalkama, J | 1 |
| Tikkanen, I | 1 |
| Fan, M | 1 |
| Kähönen, M | 1 |
| Moilanen, E | 1 |
| Pörsti, I | 1 |
| Kaneko, K | 1 |
| Kaneko, M | 1 |
| Kotaki, S | 1 |
| Mimura, T | 1 |
| Takane, H | 1 |
| Burgess, ED | 1 |
| Marentette, MA | 1 |
| Chabot, I | 1 |
| Riispere, Z | 1 |
| Vihalemm, T | 1 |
| Kullissaar, T | 1 |
| Zilmer, K | 1 |
| Zilmer, M | 1 |
| Perico, N | 1 |
| Ruggenenti, P | 5 |
| Zanabli, AR | 1 |
| Yango, A | 1 |
| Dworkin, L | 1 |
| Mohanram, A | 2 |
| Toto, RD | 2 |
| Nakao, N | 1 |
| Senou, H | 1 |
| Kasuga, H | 1 |
| Toriyama, T | 1 |
| Kawahara, H | 1 |
| Szucs, TD | 1 |
| Sandoz, MS | 1 |
| Keusch, GW | 1 |
| Perna, A | 1 |
| Dimitrov, BD | 1 |
| Hille, DA | 1 |
| Egan, B | 1 |
| Gleim, G | 1 |
| Panish, J | 1 |
| Kowey, PR | 1 |
| Fujihara, CK | 2 |
| Velho, M | 1 |
| Malheiros, DM | 2 |
| Zatz, R | 2 |
| Ichihara, A | 1 |
| Kaneshiro, Y | 1 |
| Takemitsu, T | 1 |
| Yoshizawa, M | 1 |
| Furukawa, T | 1 |
| Cheung, WY | 1 |
| Gibson, IW | 1 |
| Rush, D | 1 |
| Jeffery, J | 1 |
| Karpinski, M | 1 |
| Wolf, SC | 1 |
| Sauter, G | 1 |
| Risler, T | 1 |
| Brehm, BR | 1 |
| van Tol, A | 1 |
| Groen, AK | 1 |
| Dullaart, RP | 1 |
| Parvanova, A | 1 |
| Chiurchiu, C | 1 |
| Seng, WK | 1 |
| Hwang, SJ | 1 |
| Han, DC | 1 |
| Teong, CC | 1 |
| Chan, J | 2 |
| Burke, TA | 1 |
| Choi, YJ | 1 |
| Formica, RN | 1 |
| Friedman, AL | 1 |
| Lorber, MI | 1 |
| Smith, JD | 1 |
| Eisen, T | 1 |
| Bia, MJ | 1 |
| Tamura, K | 1 |
| Matsumoto, N | 1 |
| Mori, Y | 1 |
| Nishikawa, M | 2 |
| Lash, JP | 1 |
| Winkelmayer, WC | 1 |
| Avorn, J | 1 |
| Kimura, G | 1 |
| Lebel, M | 2 |
| Rodrigue, ME | 1 |
| Agharazii, M | 1 |
| Larivière, R | 2 |
| Tershakovec, AM | 1 |
| Appel, GB | 1 |
| McGill, JB | 1 |
| Mattar, AL | 1 |
| Machado, FG | 1 |
| de Jong, PE | 1 |
| Franco, R | 1 |
| Gut, A | 1 |
| Ferrari-Spadotto, A | 1 |
| Georgette, J | 1 |
| Gavras, I | 1 |
| Gavras, H | 1 |
| Sakemi, T | 1 |
| Baba, N | 1 |
| Missouris, CG | 1 |
| Ward, DE | 1 |
| Eastwood, JB | 1 |
| MacGregor, GA | 1 |
| Farthing, D | 1 |
| Sica, D | 1 |
| Fakhry, I | 1 |
| Pedro, A | 1 |
| Gehr, TW | 3 |
| Kingma, I | 1 |
| Grose, JH | 1 |
| Boucher, D | 1 |
| Goffin, E | 1 |
| Pochet, JM | 1 |
| Lejuste, P | 1 |
| De Plaen, JF | 1 |
| Guirado, L | 1 |
| Capdevilla, L | 1 |
| Martínez, JG | 1 |
| Pereira, P | 1 |
| Bravo, J | 1 |
| Pérez, R | 1 |
| Martin-Malo, A | 1 |
| Martinez, I | 1 |
| Aljama, P | 1 |
| Montenegro, J | 1 |
| Lang, SM | 2 |
| Schiffl, H | 2 |
| Jimenez, W | 1 |
| Lario, S | 1 |
| Clesca, PH | 1 |
| Rivera, F | 1 |
| Pedro, AA | 1 |
| Brophy, DF | 1 |
| Sica, DA | 2 |
| Halstenson, CE | 1 |
| Celik, A | 1 |
| Ok, E | 1 |
| Unsal, A | 1 |
| Töz, H | 1 |
| Atabay, G | 1 |
| Kato, A | 1 |
| Takita, T | 1 |
| Furuhashi, M | 1 |
| Takahashi, T | 1 |
| Maruyama, Y | 1 |
| Hishida, A | 1 |
| Krivosíková, Z | 1 |
| Dusinská, M | 1 |
| Spustová, V | 1 |
| Sebeková, K | 1 |
| Blazícek, P | 1 |
| Heidland, A | 1 |
| Dzúrik, R | 1 |
| Maillard, JO | 1 |
| Descombes, E | 1 |
| Fellay, G | 1 |
| Regamey, C | 1 |
| Mora-Macía, J | 1 |
| Cases, A | 1 |
| Calero, F | 1 |
| Barceló, P | 1 |
| Coats, AJ | 1 |
| Mitch, WE | 1 |
| Snapinn, SM | 1 |
| Bloomgarden, ZT | 1 |
| Kohzuki, M | 1 |
| Kamimoto, M | 1 |
| Wu, XM | 1 |
| Xu, HL | 1 |
| Mori, N | 1 |
| Nagasaka, M | 1 |
| Kurosawa, H | 1 |
| Minami, N | 1 |
| Kanazawa, M | 1 |
| Saito, T | 1 |
| Yoshida, K | 1 |
| Fishman, S | 1 |
| Rapoport, MJ | 1 |
| Weissgarten, J | 1 |
| Zaidenstein, R | 1 |
| Dishi, V | 1 |
| Hartzeanu, I | 1 |
| Golik, A | 1 |
| Saka, S | 1 |
| Nakamura, T | 1 |
| Ebihara, I | 1 |
| Koide, H | 1 |
| Walser, M | 1 |
| Siva, S | 1 |
| Dunn, SR | 1 |
| Sharma, K | 1 |
| Campese, VM | 1 |
| Ye, S | 1 |
| Truong, RH | 1 |
| Gamburd, M | 1 |
| Krieter, DH | 1 |
| Canaud, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Angiotensin II Blockade for the Prevention of Cortical Interstitial Expansion and Graft Loss in Kidney Transplant Recipients[NCT00067990] | Phase 4 | 153 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)[NCT00555217] | Phase 3 | 1,448 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to It was stopped primarily because of safety concerns along with low conditional power to detect a treatment effect on the primary outcome.) | ||
| [NCT00530595] | 0 participants | Interventional | Completed | ||||
| Effect of Nighttime Valsartan on Prognosis of Nocturnal Hypertension Patients Undergoing Maintenance Hemodialysis[NCT03594825] | Phase 4 | 68 participants (Anticipated) | Interventional | 2018-11-30 | Not yet recruiting | ||
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department.[NCT00437775] | 300 participants | Observational | 2007-01-31 | Recruiting | |||
| No Pharmacokinetic Interaction Between Chlorthalidone and Losartan, in Healthy Volunteers Under Fasting Conditions, Administered in Fixed Combination Against Individual Components Administered Jointly and Separately[NCT05090449] | Phase 1 | 36 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| Effect of Nighttime Losartan on Prognosis of Nocturnal Hypertension Patients Undergoing Continous Ambulatory Peritoneal Dialysis[NCT03692013] | Phase 4 | 68 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Pharmacokinetic Study of Propranolol, Losartan, and Eprosartan in Healthy Volunteers and Patients With Chronic Kidney Disease[NCT01087749] | Phase 1 | 24 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)[NCT05037695] | Phase 4 | 40 participants (Anticipated) | Interventional | 2021-07-21 | Recruiting | ||
| Determinants of Diabetic Nephropathy in American Indians[NCT01878045] | 141 participants (Actual) | Observational | 2013-11-07 | Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Doubling of the interstitial or any defined ESRD (including IF/TA) (NCT00067990)
Timeframe: Baseline to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Losartan | 6 |
| Placebo | 12 |
Number of subjects who had doubling of the interstitial or any end stage renal disease (ESRD) not attributed to interstitial fibrosis and tubular atrophy (IF/TA) (NCT00067990)
Timeframe: Baseline and 5 Years Post Transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Losartan | 7 |
| Placebo | 15 |
Time to the first event of reduction in estimated GFR of 30ml/min/1.73m*m in individuals w/a baseline estimated GFR >= 60 ml/min/1.73m*m, reduction in estimated GFR >50% in individuals w/ baseline estimated GFR <60ml/min/1.73m*m; ESRD or death. (NCT00555217)
Timeframe: From enrollemnt to time of first primary event, up to 4.5 years
| Intervention | participants (Number) |
|---|---|
| Combination of ARB and ACEI | 132 |
| Monotherapy ARB | 152 |
Time to the first event of reduction in estimated GFR of >50% (for individuals with baseline GFR <60) or reduction in GFR of >30 (for individuals with baseline GFR >= GFR 60) or ESRD. (NCT00555217)
Timeframe: From enrollment to time of first event, up to 4.5 years
| Intervention | participants (Number) |
|---|---|
| Combination of ARB and ACEI | 77 |
| Monotherapy ARB | 101 |
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
22 reviews available for losartan and Kidney Failure, Chronic
| Article | Year |
|---|---|
The association between adult-onset Still's disease and collapsing glomerulopathy: a case report.
Topics: Adolescent; Adult; Cyclosporine; Female; Fever; Humans; Kidney Diseases; Kidney Failure, Chronic; Lo | 2022 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
Clinical trials of the past decade in the management of chronic kidney disease.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyper | 2009 |
Evidence-based hypertension treatment in patients with diabetes.
Topics: Albuminuria; Antihypertensive Agents; Diabetic Angiopathies; Diabetic Nephropathies; Endothelium, Va | 2012 |
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2002 |
[Large scale clinical trials in prevention of end-stage renal disease due to type 2 diabetes with angiotensin receptor antagonists].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; | 2002 |
[Evidence for the benefits of ACE inhibitors and AII antagonists in slowing progressive renal failure in diabetes].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Com | 2002 |
Losartan in diabetic nephropathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; | 2003 |
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Topics: Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney | 2003 |
[Antihypertensive treatment in patients with diabetes mellitus].
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Bosentan; Diabetes Complications; Endothel | 2002 |
ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic | 2003 |
Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diab | 2003 |
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial | 2003 |
Advances in the treatment of diabetic renal disease: focus on losartan.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2004 |
[Therapeutic strategy for patients with stable-stage chronic kidney failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2004 |
Losartan in diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabe | 2004 |
[Kidney and hypertension--evidence based medicine].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2004 |
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
Topics: Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Health Care | 2004 |
Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2005 |
Losartan: lessons learned from the RENAAL study.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cli | 2006 |
Time to abandon microalbuminuria?
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; | 2006 |
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2001 |
62 trials available for losartan and Kidney Failure, Chronic
| Article | Year |
|---|---|
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure.
Topics: Adult; Albuminuria; Aldosterone; Allografts; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Bi | 2014 |
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic N | 2013 |
Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Ty | 2014 |
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Blood Pr | 2015 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mel | 2015 |
BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2015 |
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2008 |
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2008 |
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2008 |
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2008 |
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus | 2009 |
Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Topics: Adiponectin; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabe | 2009 |
Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.
Topics: Adult; Aged; Antihypertensive Agents; Cost Savings; Cost-Benefit Analysis; Diabetic Nephropathies; E | 2011 |
Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Child; Child, Preschool; Diarrhea; Diet Therapy; Do | 2011 |
Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Enzyme-Linked Immunosorbent Assay; | 2011 |
Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blo | 2011 |
Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Case-Cont | 2012 |
[Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Chan | 2002 |
Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Creatinine; Diabetes | 2002 |
[Effect of angiotensin II receptor antagonist (losartan) on renal function, serum potassium and blood pressure in patients with advanced renal failure: differences between patients with a serum creatinine (SCr) level higher than 3 mg/dl and those with a l
Topics: Aged; Angiotensin Receptor Antagonists; Blood Pressure; Creatinine; Female; Humans; Kidney; Kidney F | 2002 |
Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2003 |
Losartan in diabetic nephropathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; | 2003 |
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
Topics: Aged; Antihypertensive Agents; Cost Savings; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fema | 2003 |
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Topics: Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney | 2003 |
An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France.
Topics: Antihypertensive Agents; Blood Pressure; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Dia | 2003 |
The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
Topics: Adult; Amlodipine; Anemia; Angiotensin Receptor Antagonists; Antihypertensive Agents; Dose-Response | 2003 |
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2003 |
The antiproteinuric effect of losartan is systemic blood pressure dependent.
Topics: Adult; Antihypertensive Agents; Blood Pressure Determination; Dose-Response Relationship, Drug; Drug | 2003 |
Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; | 2003 |
Differing anti-proteinuric action of candesartan and losartan in chronic renal disease.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidaz | 2003 |
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.
Topics: Antihypertensive Agents; Asian People; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2004 |
Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension, Renal; Japan; Kidney Failur | 2004 |
Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium; Diabetes Mellitus, | 2004 |
Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Canada; Cost Savings; Diabetes Mellitus, Type 2; Diab | 2004 |
Incidence of hyperkalemia in high risk patients during treatment with an angiotensin converting enzyme inhibitor (Lisinopril) versus an angiotensin II receptor blocker (Losartan).
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cross-Over | 2004 |
Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.
Topics: Aged; Anemia; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Pr | 2004 |
The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Cost of Illness; Cost Savings; Cost-Benefit An | 2004 |
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
Topics: Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Health Care | 2004 |
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
Topics: Aged; Antihypertensive Agents; Cost Savings; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fema | 2004 |
Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Topics: Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Metho | 2004 |
Losartan and end-organ protection--lessons from the RENAAL study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Mellitus, Ty | 2005 |
Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients.
Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blo | 2005 |
Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Cost-Benefit Analysi | 2005 |
A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period.
Topics: Adult; Aged; Amlodipine; Blood Pressure Determination; Chi-Square Distribution; Dose-Response Relati | 2006 |
Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Collagen; Double-Blind Method; Echocardiography | 2005 |
Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fe | 2006 |
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Creatinine; | 2006 |
Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Com | 2007 |
The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.
Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2008 |
Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cyclosporine; Drug Interactions; Female; Humans; Hyp | 1998 |
Evaluation of the Losartan in Hemodialysis (ELHE) Study.
Topics: Acrylic Resins; Acrylonitrile; Adult; Aged; Aged, 80 and over; Anaphylaxis; Angiotensin Receptor Ant | 1998 |
Losartan and anaemia of end-stage renal disease.
Topics: Anemia; Antihypertensive Agents; Erythropoietin; Humans; Hypertension; Kidney Failure, Chronic; Losa | 1998 |
Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease.
Topics: Anemia; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1999 |
Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy.
Topics: Adult; Aged; Angiotensin II; Antihypertensive Agents; Blood Pressure; Chronic Disease; Endothelins; | 1999 |
The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Blood Pressure; Diastole; Female; Half-Life; Human | 2000 |
Pharmacokinetics and blood pressure response of losartan in end-stage renal disease.
Topics: Adult; Aldosterone; Antihypertensive Agents; Area Under Curve; Blood Pressure; Female; Half-Life; Hu | 2000 |
Comparison of enalapril and losartan in the treatment of posttransplant erythrocytosis.
Topics: Antihypertensive Agents; Enalapril; Female; Humans; Kidney Failure, Chronic; Kidney Transplantation; | 2000 |
No effect of losartan on response to erythropoietin therapy in patients undergoing hemodialysis.
Topics: Anemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Interactions; Erythr | 2000 |
Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Creatinine; Diastole; Dis | 2001 |
Add-on angiotensin receptor blockade with maximized ACE inhibition.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin Receptor Antagonists; Angiotens | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihy | 2002 |
Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2002 |
70 other studies available for losartan and Kidney Failure, Chronic
| Article | Year |
|---|---|
Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Experimen | 2018 |
Pathophysiological analysis of uninephrectomized db/db mice as a model of severe diabetic kidney disease.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; | 2022 |
Effects of a Losartan-Antioxidant Hybrid (GGN1231) on Vascular and Cardiac Health in an Experimental Model of Chronic Renal Failure.
Topics: Animals; Antioxidants; Fibrosis; Kidney; Kidney Failure, Chronic; Losartan; Male; Models, Theoretica | 2023 |
AT1 and AT2 receptors modulate renal tubular cell necroptosis in angiotensin II-infused renal injury mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2019 |
Evaluation of Trace Elements in Augmentation of Statin-Induced Cytotoxicity in Uremic Serum-Exposed Human Rhabdomyosarcoma Cells.
Topics: Cell Line, Tumor; Cell Survival; Cisplatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2018 |
[The 467th case: proteinuria, periungual fibromas, and facial steatadenomas].
Topics: Angiomyolipoma; Apolipoprotein L1; Creatinine; Female; Glomerulonephritis, IGA; Humans; Kidney Failu | 2019 |
Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Bilirubin; Biphenyl Compounds; Diabetes Mellitus, Typ | 2014 |
Angiotensin II-induced hypertensive renal inflammation is mediated through HMGB1-TLR4 signaling in rat tubulo-epithelial cells.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Cell Line; Epithelial Cells; HMGB1 Protein; Hypert | 2015 |
Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, T | 2016 |
Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade.
Topics: Acute Kidney Injury; Aged; Albuminuria; Blood Pressure; Drug Therapy, Combination; Female; Glomerula | 2016 |
Increased colonic sodium absorption in rats with chronic renal failure is partially mediated by AT1 receptor agonism.
Topics: Amiloride; Angiotensin II; Animals; Colon; Epithelial Sodium Channels; Intestinal Absorption; Kidney | 2008 |
Intensive diabetes management for high-risk patients: how best to deliver?
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Delivery of Health Ca | 2009 |
Heme oxygenase-1 inducer hemin attenuates the progression of remnant kidney model.
Topics: Animals; Bone Morphogenetic Protein 7; Caspase 3; Disease Progression; Enzyme Induction; Fibrosis; G | 2009 |
CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aryl Hydrocarbon Hydr | 2009 |
[Economic impact of Losartan use in type 2 diabetic patients with nephropathy].
Topics: Angiotensin II Type 1 Receptor Blockers; Chile; Cost of Illness; Cost-Benefit Analysis; Diabetes Mel | 2009 |
Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood | 2009 |
Inhibitory effects of uraemic toxins 3-indoxyl sulfate and p-cresol on losartan metabolism in vitro.
Topics: Angiotensin II Type 1 Receptor Blockers; Aryl Hydrocarbon Hydroxylases; Cresols; Cytochrome P-450 CY | 2010 |
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2010 |
Spurious hyperkalaemia: an insight.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Chemical Analysis; False Positive Reactions; Fe | 2011 |
Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics.
Topics: Animals; Area Under Curve; Biopharmaceutics; Chromatography, Liquid; Estrone; Hepatocytes; Humans; K | 2011 |
Diabetes: Lowering serum uric acid levels to prevent kidney failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetic Nephropathies; Humans; Hyperuricemia; Kidney Failu | 2011 |
Spontaneous remission of post-transplant recurrent focal and segmental glomerulosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Child; Disease Pr | 2011 |
Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Aorta; Benzimidazoles; Be | 2012 |
Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition.
Topics: Angiotensinogen; Animals; Cresols; Epithelial-Mesenchymal Transition; Fibrosis; Gene Expression Regu | 2012 |
The effects of Losartan on oxidative stress and inflammation in non-diabetic patients undergoing chronic hemodialysis.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; C-Reactive Protein; Female; Humans; Inflammati | 2013 |
Association of renal injury with nitric oxide deficiency in aged SHR: prevention by hypertension control with AT1 blockade.
Topics: Aging; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arterioles; Hypertension, | 2002 |
Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
Topics: Angiotensin II Type 1 Receptor Blockers; Cost of Illness; Cost Savings; Cost-Benefit Analysis; Diabe | 2002 |
Effects of AT1 and AT2 receptor blockade on angiotensin II induced apoptosis of human renal proximal tubular epithelial cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Apoptosis; Cell Death; Cells, Cultured; Dose-Respo | 2002 |
Effects of a therapy with losartan and quinaprilat on the progression of chronic renal failure in rats after a single dose of uranyl nitrate or 5/6 nephrectomy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Disease | 2003 |
Angiotensin II involvement in adaptive enteric oxalate excretion in rats with chronic renal failure induced by hyperoxaluria.
Topics: Adaptation, Physiological; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biologi | 2003 |
Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atenolol; Ba | 2003 |
Efficacy of losartan in the treatment of erythrocytosis in a young adult with CRF.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Humans; | 2004 |
Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study.
Topics: Anemia; Antihypertensive Agents; Cough; Creatinine; Female; Follow-Up Studies; Humans; Hyperkalemia; | 2003 |
Achieved vs initial blood pressure in predicting renal outcomes.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2004 |
Effect of angiotensin II type 1 receptor blockade on conduit artery tone in subtotally nephrectomized rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Culture Techniques; Endothelium, Vascular; Kidney; | 2004 |
Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure.
Topics: Animals; Atenolol; Disease Models, Animal; Kidney; Kidney Cortex; Kidney Failure, Chronic; Losartan; | 2004 |
An extremely high dose of losartan affords superior renoprotection in the remnant model.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Disease Models, Anima | 2005 |
Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2005 |
Effects of combined endothelin and angiotensin II antagonism on growth factor-induced proliferation of vascular smooth muscle cells isolated from uremic rats.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibit | 2005 |
Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment.
Topics: Adult; Analysis of Variance; Apolipoproteins; Biological Transport; Case-Control Studies; Cholestero | 2006 |
Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, T | 2006 |
[AT1 receptor antagonist lorsartan and organ protection. Managing hypertension a different way].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetic Nephropathies; Humans; Hy | 2006 |
The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Cos | 2006 |
Japanese subpopulation analysis of the RENAAL, the landmark trial, is welcomed by our society.
Topics: Angiotensin II Type 1 Receptor Blockers; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabet | 2006 |
Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2006 |
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
Topics: Albuminuria; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney Fai | 2008 |
Persistent hypertension and progressive renal injury induced by salt overload after short term nitric oxide inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Disease Models, Animal; D | 2007 |
Losartan in patients with renal insufficiency.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 1995 |
Pressor mechanisms in adriamycin-induced nephropathy with hypertension in rats.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Cholesterol; Creatinine; Doxorubicin; H | 1994 |
Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Blood Urea Nitrogen; | 1993 |
Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biological Trans | 1996 |
Deterioration in renal function with enalapril but not losartan in a patient with renal artery stenosis in a solitary kidney.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Enalapr | 1997 |
Local upregulation of colonic angiotensin II receptors enhances potassium excretion in chronic renal failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Colon; Imidazoles; Kidney Fa | 1998 |
Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate.
Topics: Antihypertensive Agents; Chromatography, High Pressure Liquid; Dialysis Solutions; Humans; Imidazole | 1997 |
Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass.
Topics: Angiotensin II; Animals; Blood Pressure; Blood Vessels; Captopril; Endothelin-1; Kidney Failure, Chr | 1998 |
Aphtous ulcers of the mouth associated with losartan.
Topics: Antihypertensive Agents; Dysgeusia; Female; Humans; Hypertension; Kidney Failure, Chronic; Lisinopri | 1998 |
DNA damage of lymphocytes in experimental chronic renal failure: beneficial effects of losartan.
Topics: Angiotensin Receptor Antagonists; Animals; Biomarkers; Creatinine; DNA Damage; Free Radicals; Kidney | 2001 |
Repeated transient anuria following losartan administration in a patient with a solitary kidney.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Anuria; Humans; Hypertension, Renov | 2001 |
Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion.
Topics: Adult; Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diure | 2001 |
Anaemia due to ACE inhibitors and losartan in patients with renal failure.
Topics: Anemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trial | 1999 |
Angiotensin II receptor blockers and nephropathy trials.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; | 2001 |
Renal protective effects of chronic exercise and antihypertensive therapy in hypertensive rats with chronic renal failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
[Angiotensin II antagonist also protects the kidneys. 2 dialysis-free years for diabetics].
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Kidney Function | 2001 |
The effect of Losartan on insulin resistance and beta cell function in chronic hemodialysis patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure Determination; Female; | 2001 |
Does angiotensin II receptor antagonist Losartan suppress drinking behavior in hemodialysis patients?
Topics: Aged; Drinking Behavior; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kidney Fai | 2001 |
Preventing nephropathy in patients with type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2002 |
Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2002 |
Losartan reduces sympathetic nerve outflow from the brain of rats with chronic renal failure.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Brain; Hypothalamus, Posterior; Interleuk | 2000 |
Anaphylactic reaction during haemodialysis on AN69 membrane in a patient receiving angiotensin II receptor antagonist.
Topics: Acrylic Resins; Acrylonitrile; Anaphylaxis; Angiotensin Receptor Antagonists; Humans; Kidney Failure | 2002 |
Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as To | 2002 |